Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Rationale targeting ASCL1 in highly aggressive Neuroendocrine prostate cancer
FY 2017-18
Summary
The constant pressure on castration-resistant prostate cancer (CRPC) tumors by androgen receptor pathway inhibitors (ARPIs), such as Enzalutamide (ENZ), selects for ENZ (ENZR) resistant cells that are less dependent on the androgen receptor (AR) for growth and survival, thereby shifting the natural history of this classically AR-driven disease to an AR indifferent phenotype. Up to 40% of ARPI-resistant CRPC patients develop AR-indifferent disease including intermediate and terminally differentiated neuroendocrine prostate cancer (NEPC), for which only limited palliative treatments exist. Although NEPC rarely arises de novo, it is increasingly defined as a variant of ARPI-resistant CRPC. The lack of innovative therapies for NEPC ENZ-resistant tumors stems from our limited molecular understanding of this deadly disease. Hence, our lab developed a pre-clinical model of ENZR that captures both AR-driven as well as the AR-indifferent NEPC-like phenotype. Using this model we have been successful in identifying potentially untapped, novel therapeutic targets for the NEPC subset of CRPC patients. RNA-seq transcriptional profiling identified the transcription factor ASCL1 as strongly upregulated in ENZR NEPC-like tumors and cell lines, which was complemented by parallel findings in NEPC patient datasets. Further functional studies confirmed that ASCL1 expression is an absolute requirement for maintenance of NEPC phenotype. Our objective is to validate that ASCL1 is a potential therapeutic target in NEPC and establish a mechanism-based framework to underpin the development of a new combination regime that inhibits ASCL1 alone or in combination with standard care therapies for prostate cancer to overcome resistance to ENZ.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386639
Name
Kobelev Maxim
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Rationale targeting ASCL1 in highly aggressive Neuroendocrine prostate cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ascl1; Enzalutamide; Epigenetics; Nepc; Prostate Cancer; Transcription Factor
Abstract
The constant pressure on castration-resistant prostate cancer (CRPC) tumors by androgen receptor pathway inhibitors (ARPIs), such as Enzalutamide (ENZ), selects for ENZ (ENZR) resistant cells that are less dependent on the androgen receptor (AR) for growth and survival, thereby shifting the natural history of this classically AR-driven disease to an AR indifferent phenotype. Up to 40% of ARPI-resistant CRPC patients develop AR-indifferent disease including intermediate and terminally differentiated neuroendocrine prostate cancer (NEPC), for which only limited palliative treatments exist. Although NEPC rarely arises de novo, it is increasingly defined as a variant of ARPI-resistant CRPC. The lack of innovative therapies for NEPC ENZ-resistant tumors stems from our limited molecular understanding of this deadly disease. Hence, our lab developed a pre-clinical model of ENZR that captures both AR-driven as well as the AR-indifferent NEPC-like phenotype. Using this model we have been successful in identifying potentially untapped, novel therapeutic targets for the NEPC subset of CRPC patients. RNA-seq transcriptional profiling identified the transcription factor ASCL1 as strongly upregulated in ENZR NEPC-like tumors and cell lines, which was complemented by parallel findings in NEPC patient datasets. Further functional studies confirmed that ASCL1 expression is an absolute requirement for maintenance of NEPC phenotype. Our objective is to validate that ASCL1 is a potential therapeutic target in NEPC and establish a mechanism-based framework to underpin the development of a new combination regime that inhibits ASCL1 alone or in combination with standard care therapies for prostate cancer to overcome resistance to ENZ.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kobelev, Maxim
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~